1
Clinical Trials associated with HER2/MUC1 dual-target CAR-NK(Beijing Biotech/Essen BioTech)Phase 1/2, Biomarker-guided, Open-label Study of Allogeneic Dual-target CAR-NK Cells Directed Against HER2/ERBB2, MUC1, and/or ROR1 in Patients With Advanced or Metastatic Breast Cancer (Including HER2-positive and Triple-negative Disease).
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.
100 Clinical Results associated with HER2/MUC1 dual-target CAR-NK(Beijing Biotech/Essen BioTech)
100 Translational Medicine associated with HER2/MUC1 dual-target CAR-NK(Beijing Biotech/Essen BioTech)
100 Patents (Medical) associated with HER2/MUC1 dual-target CAR-NK(Beijing Biotech/Essen BioTech)
100 Deals associated with HER2/MUC1 dual-target CAR-NK(Beijing Biotech/Essen BioTech)